Table 1.
Basic characteristics of local patients with HDV diagnosed between July 2009 and December 2021
| Parameters (n=61) | Number of patients, n (%) |
|---|---|
| Mean age in years, (range) | 44.8 (23–76) |
| Sex | |
| Male | 26 (42%) |
| Female | 35 (58%) |
| Ethnicity | |
| Asian | 13 (21%) |
| Black | 8 (13%) |
| Mixed | 9 (15%) |
| White | 13 (21%) |
| Unknown | 18 (30%) |
| Virology | |
| HBS Ag | 61 (100%) |
| HBeAg +ve | 14 (23%) |
| HBeAg –ve | 47 (77%) |
| Hep e Ag Ab +ve | 46 (75%) |
| Hep e Ag Ab –ve | 15 (25%) |
| HBV core Ab +ve | 59 (89%) |
| HCV Ab +ve | 2 (3%) |
| HIV Ag/Ab | 0 (0%) |
| HDV virology | |
| HDV IgG Ab | 61 (100%) |
| HDV RNA +ve | 22 (36%) |
| Staging of liver disease | |
| Cirrhosis on imaging | 30 (49%) |
| Mean transient elastography at diagnosis in kPa (range) | 6.44 (2.7–23.2) |
| Chronic HBV therapy | |
| Tenofovir | 20 (33%) |
| Entecavir | 14 (23%) |
| Lamivudine | 7 (12%) |
| HDV-specific therapy | |
| IFN-α | 17 (28%) received treatment; 13 (21%) did not continue because of adverse effects |
| Liver transplantation | 13 (21%) |
| Death | 3 (5%) |
| Blood tests at diagnosis | Mean value (range) |
| AST (U/L) | 54.64 (14–199) |
| ALT (U/L) | 98.18 (9–2236) |
| ALP (U/L) | 72 (28–201) |
| Bilirubin (μmol/L) | 18.93 (2–319) |
| Albumin (g/L) | 43 (23–56) |
| Sodium (mmol/L) | 140.26 (128–146) |
| Creatinine (mmol/L) | 68.95 (36–164) |
| INR | 1.18 (0.9–3.7) |
| Hb (g/L) | 131.63 (79–169) |
| MCV (fL) | 86.2 (65–103.1) |
| Neutrophils (109/L) | 2.82 (0.4–7.7) |
| Lymphocytes count (109/L) | 1.53 (0.4–3.3) |
| Total white cell count (109/L) | 4.84 (1.7–11.2) |
| Platelet count (109/L) | 157.1 (29–383) |
Ab = antibody; Ag = antigen; ALP= alkaline phosphatase; ALT = alanine transaminase; AST = aspartate transaminase; HCV = hepatitis C virus; HDV = hepatitis D virus; HB = hepatitis B virus; IFN = inteferon; INR = international normalised ratio.